Form 4: Lyra Therapeutics CFO Executes Pre-Planned Stock Sale for Tax Obligations

Lyra Therapeutics' Chief Financial Officer, Jason Cavalier, sold 684 shares of common stock on July 10, 2025, at $8.91 per share to cover tax obligations related to restricted stock unit vesting, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Jason Cavalier, Chief Financial Officer of Lyra Therapeutics, Inc. (LYRA), disposed of 684 shares of common stock.
• The transaction occurred on July 10, 2025, with shares sold at a price of $8.91 per share.
• The sale was executed to cover taxes upon the vesting of restricted stock units (RSUs).
• This transaction was conducted pursuant to a mandatory Rule 10b5-1 trading instruction, which was adopted by Mr. Cavalier on January 1, 2025.
• Following this transaction, Mr. Cavalier beneficially owns 519,316 shares of Lyra Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine, non-discretionary sale by an insider to cover tax liabilities associated with RSU vesting, executed under a pre-established 10b5-1 plan. This type of transaction does not typically indicate a change in management's outlook on the company's prospects.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 plan, indicating a non-discretionary sale for tax purposes rather than a discretionary sale based on market outlook.

Negatives

• No specific negatives are indicated by this routine, tax-related stock sale.

Risks

• No specific risks are mentioned in this filing related to the company's operations or financial health; the filing pertains solely to an insider transaction.

Future Outlook

No forward-looking statements or guidance are provided in this SEC Form 4 filing, as it is solely focused on an insider transaction.

Management Comments

• Shares were sold to cover taxes upon the vesting of restricted stock units ('RSUs') pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale of 684 shares by the CFO is a minor dilution relative to the total shares outstanding and is a routine event for tax purposes, unlikely to have a significant direct impact on shareholder value or perception.

Key Dates

Keywords

Lyra Therapeutics, LYRA, Jason Cavalier, CFO, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Rule 10b5-1 Plan, Tax Obligations